Fate Therapeutics

Fate Therapeutics is a clinical-stage biopharmaceutical company developing programmed cellular immunotherapies for cancer and autoimmune diseases. It uses its iPSC (induced pluripotent stem cell) product platform to make off-the-shelf, engineered cell therapies. Its pipeline includes iPSC-derived CAR NK and CAR T-cell product candidates, such as FT819 and FT522.